Tina Albertson compensation by year
Lyell Immunopharma Summary Compensation Table · the one fiscal year held| Component | FY2023 |
|---|---|
| Salary | $473,444 |
| Bonus | $42,097 |
| Stock awards | $0 |
| Option awards | $1,149,820 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $726,042 |
| Total | $2,391,403 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Lyell Immunopharma, Inc. DEF 14A filed April 22, 2024, accession 0001140361-24-021008, and prior-year filings.
How this page was built: the Lyell Immunopharma, Inc. filed document, accession 0001140361-24-021008. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2024.
Lyell Immunopharma’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Charles Newton | Chief Financial Officer | $4,317,424 |
| Matthew Lang | Chief Business Officer | $4,008,353 |
| Stephen Hill | Chief Operating Officer | $3,108,128 |
| Lynn Seely | President, Chief Executive Officer and Director | $2,647,476 |
| Tina Albertson · this page | Former Chief Medical Officer and Head of Development | $2,391,403 |
| Gary Lee | Chief Scientific Officer | $2,226,356 |
The full Lyell Immunopharma compensation record
free company briefThis page is one person within Lyell Immunopharma's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Lyell Immunopharma proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Lyell Immunopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.